$3.46
7.45% day before yesterday
Nasdaq, Dec 27, 10:15 pm CET
ISIN
US16934W1062
Symbol
CMRX
Sector
Industry

Chimerix, Inc. Stock price

$3.46
+2.56 282.32% 1M
+2.57 289.16% 6M
+2.50 259.48% YTD
+2.51 265.17% 1Y
-3.37 49.34% 3Y
+1.42 69.61% 5Y
-34.78 90.95% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.24 7.45%
ISIN
US16934W1062
Symbol
CMRX
Sector
Industry

Key metrics

Market capitalization $311.18m
Enterprise Value $176.68m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1,104.25
P/S ratio (TTM) P/S ratio 1,944.88
P/B ratio (TTM) P/B ratio 2.29
Revenue growth (TTM) Revenue growth -85.98%
Revenue (TTM) Revenue $160.00k
EBIT (operating result TTM) EBIT $-92.83m
Free Cash Flow (TTM) Free Cash Flow $-70.62m
Cash position $136.23m
EPS (TTM) EPS $-0.94
P/E forward negative
P/S forward 328.32
EV/Sales forward 186.41
Short interest 0.76%
Show more

Is Chimerix, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Chimerix, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Chimerix, Inc. forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a Chimerix, Inc. forecast:

Buy
100%

Financial data from Chimerix, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.16 0.16
86% 86%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 20 20
18% 18%
12,750%
- Research and Development Expense 73 73
0% 0%
45,350%
-93 -93
3% 3%
-58,025%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -93 -93
3% 3%
-58,016%
Net Profit -84 -84
2% 2%
-52,244%

In millions USD.

Don't miss a Thing! We will send you all news about Chimerix, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Chimerix, Inc. Stock News

Positive
Seeking Alpha
17 days ago
Chimerix, Inc.'s dordaviprone shows promise in treating H3 K27M-positive glioma, with a potential FDA approval and commercial launch by Q3 2025. CMRX's strong clinical data and high unmet need in diffuse midline glioma bolster confidence in FDA approval, despite potential timeline uncertainties. Financially, CMRX has a cash runway of 6–7 quarters, sufficient to reach an FDA decision, but risks ...
Neutral
GlobeNewsWire
19 days ago
Potential Approval in Q3 2025 in Recurrent H3 K27M-Mutant Diffuse Glioma Submission Plan Follows Productive and Collaborative Pre-NDA Interactions with FDA Company to Host Conference Call on Tuesday, December 10 at 8:30 AM ET DURHAM, N.C., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and...
Neutral
GlobeNewsWire
22 days ago
DURHAM, N.C., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on December 2, 2024, the Compensation Committee of Chimerix's Board of Directors granted inducement awards to three new employees of non-statutory stock options to purchase up to a total of 385,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved th...
More Chimerix, Inc. News

Company Profile

Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R. Painter, III and Timothy Wollaeger in April 2000 and is headquartered in Durham, NC.

Head office United States
CEO Michael Andriole
Employees 72
Founded 2000
Website www.chimerix.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today